SynthesisCellular and molecular neurobiology2026
Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies.
Synthesis in Cellular and molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Alzheimer's disease (AD) is the most common cause of dementia, and its overall incidence is rising as the proportion of older individuals in the population increases. Traditional diagnostic methods, such as lumbar puncture and neuroimaging, are costly and invasive, driving the search for blood-based biomarkers (BBB) for early diagnosis. The quantification of these biomarkers requires ultrasensitive techniques, such as the single-molecule array (SIMOA) platform. This systematic review synthesizes the available evidence on the biomarkers β-amyloid (Aβ42, Aβ40, and their ratio), tau protein (t-Tau, p-Tau181, p-Tau231, p-Tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) in studies analyzing their blood concentrations using SIMOA, regardless of the platform model (SR-X, HD-1, HD-X). Findings support the potential of plasma biomarkers as an alternative or complement to invasive methods, although further validation is required before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.